Alexandra C W Reitz1, Jeffrey M Switchenko2, Theresa W Gillespie1,3. 1. Department of Surgery, 160352Emory University School of Medicine, Atlanta, GA, USA. 2. Department of Biostatistics and Bioinformatics, 25798Emory University Rollins School of Public Health, Atlanta, GA, USA. 3. Department of Hematology and Medical Oncology, 12239Emory University School of Medicine and Winship Cancer Institute, Atlanta, GA, USA.
Abstract
METHODS: This retrospective study of 86 413 patients (40-64 years old) undergoing surgical resection for a new diagnosis of invasive, nonmetastatic colon cancer included in the National Cancer Database (NCDB) from 2010 to 2015 compared overall survival (OS) in MES to NES. Cox proportional hazard models, fit for OS, and propensity score-matching (PSM) analysis were performed. RESULTS: In this sample, 51 297 cases (59.2%) lived in MES and 35 116 (40.8%) in NES. Medicaid expansion states had earlier pathological stage compared to NES (stage I 25.38% vs 24.17%, stage II 32.93 vs 33.4%, and stage III 41.69 vs 42.43%; P < .001). 5-year OS in MES was higher than NES (79.1% vs 77.3%; P < .001); however, on both multivariable analysis (MVA) and PSM analysis, MES did not have significantly different OS from NES (hazard ratio (HR), .99, 95% confidence interval (CI), .95-1.03; P = .570; HR, .99, 95% CI, .95-1.03; P = .68). CONCLUSION: Among NCDB patients with invasive, nonmetastatic colon cancer residing in MES at time of diagnosis was associated with earlier pathological stage. However, on both MVA and PSM analysis, OS was not significantly different in MES vs NES. Research on patient outcomes, such as receipt of guideline concordant care, can further inform the impact of insurance coverage expansion efforts on cancer outcomes.
METHODS: This retrospective study of 86 413 patients (40-64 years old) undergoing surgical resection for a new diagnosis of invasive, nonmetastatic colon cancer included in the National Cancer Database (NCDB) from 2010 to 2015 compared overall survival (OS) in MES to NES. Cox proportional hazard models, fit for OS, and propensity score-matching (PSM) analysis were performed. RESULTS: In this sample, 51 297 cases (59.2%) lived in MES and 35 116 (40.8%) in NES. Medicaid expansion states had earlier pathological stage compared to NES (stage I 25.38% vs 24.17%, stage II 32.93 vs 33.4%, and stage III 41.69 vs 42.43%; P < .001). 5-year OS in MES was higher than NES (79.1% vs 77.3%; P < .001); however, on both multivariable analysis (MVA) and PSM analysis, MES did not have significantly different OS from NES (hazard ratio (HR), .99, 95% confidence interval (CI), .95-1.03; P = .570; HR, .99, 95% CI, .95-1.03; P = .68). CONCLUSION: Among NCDB patients with invasive, nonmetastatic colon cancer residing in MES at time of diagnosis was associated with earlier pathological stage. However, on both MVA and PSM analysis, OS was not significantly different in MES vs NES. Research on patient outcomes, such as receipt of guideline concordant care, can further inform the impact of insurance coverage expansion efforts on cancer outcomes.
Authors: Yasmin A Zerhouni; Quoc-Dien Trinh; Stuart Lipsitz; Joel Goldberg; Jennifer Irani; Ronald Bleday; Adil H Haider; Nelya Melnitchouk Journal: Dis Colon Rectum Date: 2019-01 Impact factor: 4.585
Authors: Rebecca L Siegel; Ahmedin Jemal; Richard C Wender; Ted Gansler; Jiemin Ma; Otis W Brawley Journal: CA Cancer J Clin Date: 2018-07-10 Impact factor: 508.702
Authors: Katherine Mallin; Amanda Browner; Bryan Palis; Greer Gay; Ryan McCabe; Leticia Nogueira; Robin Yabroff; Lawrence Shulman; Matthew Facktor; David P Winchester; Heidi Nelson Journal: Ann Surg Oncol Date: 2019-02-08 Impact factor: 5.344
Authors: Anthony S Robbins; Alexandre L Pavluck; Stacey A Fedewa; Amy Y Chen; Elizabeth M Ward Journal: J Clin Oncol Date: 2009-05-26 Impact factor: 44.544